Drug Desensitization, Rapid Induction of Tolerance

Determines desensitization candidacy by reaction type and medical necessity, risk-stratifies by index reaction severity, and sequences the premedication and protocol approach per the 2022 drug allergy practice parameter and published rapid desensitization experience.

Evidence tier: Guideline-derived.

Decision points

  • What type of hypersensitivity reaction occurred?
  • Is the drug medically necessary with no safe equivalent?
  • Severity of index reaction?

Do-not-miss pitfalls

  • Never attempt desensitization for SCAR reactions (SJS, TEN, DRESS, AGEP), T-cell-mediated mechanisms are not amenable to tolerance induction; re-exposure is potentially fatal.
  • Desensitization creates a TEMPORARY tolerant state lost within 24-72 h of stopping the drug. Stopping and restarting is pharmacologically equivalent to re-sensitization, always warn patients before every drug course.
  • Do NOT use antihistamine alone for breakthrough anaphylaxis during desensitization, epinephrine is first-line; antihistamine delay is the leading cause of preventable fatalities.
  • Grade 3-4 index reaction = inpatient/ICU-only setting. Never perform high-risk desensitization in an ambulatory infusion center without immediate resuscitation capability.
  • Beta-blockers impair epinephrine response to breakthrough anaphylaxis, hold if clinically feasible before starting the protocol.
  • A negative skin test does not eliminate anaphylaxis risk, always perform desensitization with full emergency readiness regardless of skin-test result.
  • Chemotherapy and biologic desensitization (taxanes, platinum salts, monoclonal antibodies) should only be performed at centers with specific protocol experience, antibiotic protocols are not directly transferable.
  • Tolerant state is drug-specific, being desensitized to carboplatin does not confer tolerance to oxaliplatin or other platinum agents; each requires its own desensitization.

Evidence & citations

  1. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333-1393. PMID 36122788
  2. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-580. PMID 18502492
  3. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312(19):1229-1232. PMID 3921835

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.